12,584 Shares in Theravance Biopharma, Inc. (NASDAQ:TBPH) Bought by Bleakley Financial Group LLC

Bleakley Financial Group LLC acquired a new position in Theravance Biopharma, Inc. (NASDAQ:TBPH) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 12,584 shares of the biopharmaceutical company’s stock, valued at approximately $141,000.

Several other institutional investors have also recently added to or reduced their stakes in TBPH. Price T Rowe Associates Inc. MD boosted its holdings in shares of Theravance Biopharma by 2.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 37,916 shares of the biopharmaceutical company’s stock valued at $412,000 after buying an additional 948 shares during the period. UBS Group AG raised its position in shares of Theravance Biopharma by 45.0% during the 1st quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,101 shares during the period. Legal & General Group Plc lifted its holdings in shares of Theravance Biopharma by 2.6% in the 2nd quarter. Legal & General Group Plc now owns 58,904 shares of the biopharmaceutical company’s stock worth $534,000 after purchasing an additional 1,516 shares during the last quarter. Royal Bank of Canada boosted its position in Theravance Biopharma by 33.8% during the 2nd quarter. Royal Bank of Canada now owns 6,532 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 1,649 shares during the period. Finally, Principal Financial Group Inc. boosted its position in Theravance Biopharma by 10.5% during the 3rd quarter. Principal Financial Group Inc. now owns 18,637 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 1,764 shares during the period. Institutional investors own 99.10% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on TBPH shares. Evercore ISI cut Theravance Biopharma from an “outperform” rating to an “inline” rating in a research note on Monday, January 8th. BTIG Research started coverage on shares of Theravance Biopharma in a research report on Friday, April 12th. They issued a “buy” rating and a $21.00 price objective on the stock.

Theravance Biopharma Stock Performance

Shares of TBPH stock opened at $9.69 on Wednesday. Theravance Biopharma, Inc. has a 1 year low of $8.21 and a 1 year high of $12.03. The firm has a market capitalization of $470.55 million, a PE ratio of -9.99 and a beta of 0.36. The stock has a fifty day moving average of $8.96 and a two-hundred day moving average of $9.66.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The company had revenue of $17.57 million during the quarter, compared to analyst estimates of $17.49 million. Theravance Biopharma had a negative return on equity of 19.31% and a negative net margin of 96.12%. Equities research analysts predict that Theravance Biopharma, Inc. will post -0.83 earnings per share for the current fiscal year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.